Trial reportInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2024
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Trial report in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment
A Retrospective Study Exploring the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Meta-Analysis of All Randomized Clinical Trials with Subgroup Analysis by Patient Profile.Oncology research · 2026Pooled it
- Efficacy of Poly(ADP-ribose) Polymerase Inhibitors According to Clinical Risk in Newly Diagnosed, Advanced Ovarian Cancer: A Meta-analysis of Phase III Clinical Trials.Annals of surgical oncology · 2026Pooled it
- Efficacy of Poly(ADP-ribose) Polymerase Inhibitors According to Clinical Risk in Newly Diagnosed, Advanced Ovarian Cancer: A Meta-analysis of Phase III Clinical Trials.Annals of surgical oncology · 2026Pooled it
- Impact of Olaparib, Niraparib, Rucaparib therapies on Newly Diagnosed and Relapsed Ovarian Cancer -Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.European journal of cancer (Oxford, England : 1990) · 2025Trial
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2024Trial
- Real-world outcomes in patients with advanced epithelial ovarian cancer receiving niraparib as first-line maintenance: a European retrospective cohort study.ESMO real world data and digital oncology · 2026Article
- Cumulative cytotoxic chemotherapy exposure after the introduction of PARP inhibitors in advanced high-grade serous tubo-ovarian and primary peritoneal carcinoma: A descriptive single-center historical cohort study.Molecular and clinical oncology · 2026Article
- [Update on ovarian cancer].Pathologie (Heidelberg, Germany) · 2026Review
- Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers · 2026Review
- Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- Programmed Death-Ligand 1 Expression across Multiple Assays in Ovarian Cancer: A Comparative Analysis.Cancer research and treatment · 2026Article
- Ovarian cancer.Nature reviews. Disease primers · 2026Review
- Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective.Biomarker research · 2026Review
- Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data.Oncology research · 2026Article
- PARP inhibitor maintenance in first-line ovarian cancer therapy: emerging standards and strategies to overcome resistance.American journal of cancer research · 2026Review
- U-shaped prognostic signature: baseline platelet count and morphological parameters predict ovarian cancer outcomes in a 265-patient cohort.Frontiers in oncology · 2026Article
- Article
- Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the Global Burden of Disease Study 2021.International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn the PAOLA-1/ENGOT-ov25 trial (NCT02477644), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and homologous recombination deficiency (HRD)-positive tumors, irrespective of clinical risk. Subsequently, a clinically meaningful improvement in overall survival was reported with olaparib plus bevacizumab in the HRD-positive subgroup. We report updated progression-free survival and overall survival by clinical risk and HRD status.
methodsPatients in clinical response after first-line platinum-based chemotherapy plus bevacizumab received maintenance olaparib (up to 24 months) plus bevacizumab (up to 15 months in total) or placebo plus bevacizumab. This
resultsOf 806 randomized patients, 74% were higher-risk and 26% were lower-risk. In higher-risk HRD-positive patients, the hazard ratio (HR) for progression-free survival was 0.46 (95% confidence interval (95% CI) 0.34 to 0.61), with 5-year progression-free survival of 35% with olaparib plus bevacizumab versus 15% with bevacizumab alone; and the HR for overall survival was 0.70 (95% CI 0.50 to 1.00), with 5-year overall survival of 55% versus 42%, respectively. In lower-risk HRD-positive patients, the HR for progression-free survival was 0.26 (95% CI 0.15 to 0.45), with 5-year progression-free survival of 72% with olaparib plus bevacizumab versus 28% with bevacizumab alone; and the HR for overall survival was 0.31 (95% CI 0.14 to 0.66), with 5-year overall survival of 88% versus 61%, respectively. No benefit was seen in HRD-negative patients regardless of clinical risk.
conclusionThis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.